

253 Assessed for eligibility

101 Excluded  
89 Did not meet inclusion criteria  
12 Refused to participate

152 Enrolled and assigned

86 Allocated to AC-1202

66 Allocated to placebo

3 Lost to follow-up  
35 Discontinued  
20 Adverse events  
8 Withdrew consent  
2 Perceived lack of efficacy  
1 Protocol violation  
1 Relocation  
3 Other

Of these 38, 9 lacked a post-Baseline visit and were not analyzed for efficacy

2 Lost to follow-up  
12 Discontinued  
4 Adverse events  
5 Withdrew consent  
2 Perceived lack of efficacy  
1 Protocol violation  
0 Other

Of these 14, 3 lacked a post-Baseline visit and were not analyzed for efficacy

77 Analyzed

63 Analyzed

ITT Population

67 APOE Genotyped

57 APOE Genotyped

ITT/Genotyped Population